Escolar Documentos
Profissional Documentos
Cultura Documentos
31 July 2013
147
ROSUVASTATIN CALCIUM
Rosuvastatinum calcicum
F
C44H54CaF 2N6012S2
[14 7098-20-2]
M, 1001
DEFINITION
Ca lei um bis[ (3R ,5 S, 6E)-7 -[4-( 4-fl uorophenyl )-2-[ methyl( methylsu lfonyl )ami no ]-6-(propan-2yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate].
Content: 97.0 per cent to 102.0 per cent (anhydrous substance).
CHARACTERS
Appearance: white or almost white, hygroscopic powder.
Solubility: slightly soluble in water, freely soluble in methylene chloride, practically insoluble in
anhydrous ethanol.
IDENTIFICATION
148
Reference solution (e). In order to prepare impurity C in situ, heat 0.25 g of the substance to be
examined at 50 oc for 7 days in amber glassware with a porous coveri57J. Dissolve 50 mg in 11 ml
of acetonitrile for chromatography R, add 3.0 ml of reference solution (c) and 1.0 ml of reference
solution (d). Dilute to 50.0 ml with water for chromatography R.
Column:
- size: I= 0.15 m, 0 = 3.0 mm;
- stationary phase: base-deactivated end-capped octadecylsilyl silica gel for chromatography R
(3 1Jm)I5BJ;
- temperature: 40
oc.
Mobile phase:
- mobile phase A: 1 per cent \IN solution of trifluoroacetic acid R, acetonitrile for
chromatography R, water for chromatography R (1 :29:70 \I!\.IN);
- mobile phase 8: 1 per cent \IN solution of trifluoroacetic acid R, water for chromatography R,
acetonitrile for chromatography R (1 :24:75 \I!\.IN);
Time
Mobile phase A
Mobile phase B
(per cent 11/V)
(min)
0-30
100
30-50
100--+ 60
0--+ 40
50-60
60--+ 0
40--+ 100
60- 75
100
149
The following chromatogram is shown for information but will not be published in the European
Pharmacopoeia.
2
10
20
30
40
50
1. impurity A
3. impurity B
5. impurity E
2. rosuvastatin
4. impurity C
6. impurity J
ro
7. impurity F
Figure 2631.-1. -Chromatogram for the test for related substances of rosuvastatin calcium:
reference solution (e) spiked with impurities E, F and J
Enantiomeric purity. Liquid chromatography (2.2.29). Prepare the solutions immediately before
use and protect them from light throughout the test.
Solvent mixture: acetonitrile for chromatography R, water for chromatography R (25:75 11/V).
Test solution. Dissolve 25.0 mg of the substance to be examined in 6 ml of acetonitrile for
chromatography Rand dilute to 25.0 ml with water for chromatography R.
Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with the solvent mixture.
Dilute 1.0 ml of this solution to 10.0 ml with the solvent mixture.
Reference solution (b). Dissolve 5 mg of rosuvastatin impurity G CRS in a mixture of 12 ml
of acetonitrile for chromatography Rand 10 ml of water for chromatography R with the aid of
ultrasound and dilute to 50.0 ml with water for chromatography R.
Reference solution (c). To 25 mg of the substance to be examined add 1.0 ml of reference
solution (b), 6 ml of acetonitrile for chromatography Rand dissolve with the aid of ultrasound;
dilute to 25 ml with water for chromatography R.
Column:
- size: I= 0.15 m, 0
=4.6 mm;
oc.
Mobile phase: acetonitrile for chromatography R, 0.1 per cent \IN solution of trifluoroacetic
acid R (25:75 11/V).
Flow rate: 0.5 ml/min.
(59) Chiralcel OJ-RH is suitable.
oo
m~
150
.A
I
A.l
/"'
10
20
30
40
50
60
70
1. impurity G
2. rosuvastatin
Figure 2631.-2. -Chromatogram for the test for enantiomeric purity of rosuvastatin calcium:
reference solution (c)
min
151
ASSAY
Liquid chromatography (2.2.29) as described in the test for related substances with the following
modification.
Specified impurities: A, B, C, G.
Other detectable impurities (the following substances would, if present at a sufficient level,
be detected by one or other of the tests in the monograph. They are limited by the general
acceptance criterion for other/unspecified impurities and/or by the general monograph
Substances for pharmaceutical use (2034). It is therefore not necessary to identify these
impurities for demonstration of compliance. See also 5. 10. Control of impurities in substances for
pharmaceutical use): 0, E, F, H, I, J.
A. (3R ,5S, 6E)-7 -[ 4-( 4-fl uorophenyl )-2-[[(2-hyd roxy-2-methyl propyl )sulfonyl]( methyl )ami no ]-6(propan-2-yl )pyri midi n-5-yl]-3, 5-d ihyd roxyhept -6-enoic acid,
and enantiomer
B. (3RS,5RS,6E)-7 -[ 4-( 4-fluorophenyl)-2-[methyl( methylsulfonyl)amino ]-6-(propan-2yl )pyri midi n-5-yl]-3, 5-d ihyd roxyhept -6-eno ic acid,
C. (3R ,6E)-7 -[ 4-( 4-fl uorophenyl )-2-[ methyl( methylsu lfonyl )ami no ]-6-(pro pan-2-yl )pyri midi n-5-yl]3-hydroxy-5-oxohept-6-enoic acid,
152
D. N-[4-(4-fluorophenyi)-5-[(E)-2-[(2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethenyl]-6(propan-2-yl)pyrimidin-2-yi]-N-methylmethanesulfonamide,
F
H
OH
G. (3S,5R,6E)-7 -[ 4-( 4-fluorophenyl)-2-[methyl( methylsulfonyl)amino ]-6-(propan-2-yl)pyrimid in-5yl]-3, 5-d ihyd roxyhept-6-eno ic acid,
F
OH
H
and epimer at
H. (3R ,5R S)-5-[8-fl uoro-2-[ methyl( methylsu lfonyl )ami no ]-4-(propan-2-yl )-5, 6dihydrobenzo[h]quinazolin-6-yl]-3,5-dihydroxypentanoic acid,
153
OH
and epi mer at
I. (3S,5RS)-5-[8-fluoro-2-[methyl(methylsulfonyl)amino]-4-(propan-2-yl)-5,6dihydrobenzo[h]quinazolin-6-yl]-3,5-dihydroxypentanoic acid,
F
J. (3R,5S,6E)-7 -[ 4-( 4-fluorophenyi)-2-[([(E)-2-[4-( 4-fluorophenyl)-2-[methyl( methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]ethenyl]sulfonyl)(methyl)amino]-6-(propan-2-yl)pyrim id in-5-yl]-3, 5-d ihyd roxyhept -6-e noic acid.